Globe News Wire
14 Jun 2026, 18:45 UTC · 22w ago
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Impact · against what's priced in
The long-term efficacy and safety data for PALSONIFY reduce the clinical risk profile for Crinetics, supporting its competitive positioning in the acromegaly market. The addition of combination therapy data and tumor stabilization results provides a expanded clinical value proposition beyond simple IGF-1 control.
- CRNX+0.60
No priced-in read yet





